Famciclovir: Oral antiviral agent as prodrug of penciclovir
Famciclovir is an oral prodrug that is rapidly converted in the body to penciclovir, the actual antiviral active metabolite. It was approved in 1994 and is a central therapeutic option against herpesvirus infections, particularly herpes zoster, recurrent herpes genitalis, and herpes labialis. Known brand names are Famvir and numerous generics.
Famciclovir, together with aciclovir and valaciclovir, is part of standard therapy for herpes simplex and varicella zoster virus infections. Compared to aciclovir, famciclovir offers significantly better oral bioavailability (approximately 77 percent versus 15 to 30 percent), which allows less frequent dosing and improves treatment adherence. The antiviral efficacy is clinically comparable to aciclovir and valaciclovir for most indications.
Mechanism of action
After oral administration, famciclovir is rapidly converted to penciclovir in the intestine and liver through esterase and aldehyde oxidase activity. Penciclovir is an acyclic guanosine analogue that is phosphorylated in virus-infected cells by viral thymidine kinase. This is followed by two further phosphorylations by cellular kinases to penciclovir triphosphate, the actual active form.
Penciclovir triphosphate competitively inhibits viral DNA polymerase and is incorporated into the growing viral DNA strand without terminating it as a chain terminator (unlike aciclovir). DNA polymerase inhibition effectively blocks viral replication. Since viral thymidine kinase is only present in infected cells, selectivity for viral infections is high and toxicity for non-infected cells is low.
Pharmacokinetically, famciclovir has the aforementioned bioavailability of approximately 77 percent. The half-life of penciclovir is two hours, but intracellular penciclovir triphosphate persists for 7 to 20 hours, which allows infrequent dosing. Elimination is renal.
Indications
- Herpes zoster (shingles) in adults: Therapy within the first 72 hours after rash onset
- Postherpetic neuralgia: Famciclovir reduces the risk and duration of postherpetic neuralgia with early therapy
- Herpes genitalis: Episodic therapy and suppressive therapy for frequent recurrences
- Herpes labialis: Acute therapy in adults
- Herpes simplex in immunocompromised: also in HIV positive patients
Dosage and administration
Herpes zoster: 500 mg three times daily for 7 days, preferably start within the first 72 hours after onset of typical skin manifestations.
Herpes genitalis first episode: 250 mg three times daily for 5 days. Recurrence: 1,000 mg twice daily for 1 day (single day therapy). Suppressive therapy: 250 mg twice daily, long term.
Herpes labialis: 1,500 mg as single dose at the first signs.
Renal insufficiency: Dose adjustment based on eGFR. With or without food: Absorption not significantly affected.
Side effects
Frequent: Headache, nausea, diarrhea, abdominal pain, fatigue, rash, pruritus.
Occasional: Dizziness, hallucinations, confusion (especially in elderly or renal insufficiency), hepatotoxicity with elevated liver transaminases, thrombocytopenia.
Rare: Acute kidney failure, Stevens Johnson syndrome, anaphylactoid reactions.
Important: In elderly patients and those with renal insufficiency, the risk of CNS side effects such as confusion or hallucinations increases, therefore dose adjustment according to eGFR is necessary.
Drug interactions
- Probenecid: Prolongs penciclovir half-life by inhibiting renal tubular secretion
- Other nephrotoxic agents (aminoglycosides, NSAIDs, cyclosporine): Additive nephrotoxicity risk
- Theophylline: Theoretical level changes, clinically of little relevance
- Digoxin: Clinically little relevant interaction
- Other antiviral agents (aciclovir, valaciclovir): Do not prescribe together, additive effect possible
Special precautions
Pregnancy and breastfeeding: Data limited, use if necessary after individual risk-benefit assessment. With clear indication (e.g., severe herpes zoster infection during pregnancy), therapy is not withheld. During breastfeeding, aciclovir is preferred due to better data.
Early therapy: The efficacy of famciclovir is better the earlier therapy is started after symptom onset. For herpes zoster, therapy should ideally be started within 72 hours after rash onset, for herpes genitalis and labialis at the first prodromal symptoms.
Suppressive therapy: In frequent genital herpes recurrences (more than 6 per year), suppressive famciclovir therapy demonstrably reduces frequency and severity of episodes as well as transmission risk to sexual partners.
Postherpetic neuralgia: Early antiviral therapy in herpes zoster not only reduces acute symptoms but also reduces the risk and duration of postherpetic neuralgia, a painful complication that can persist for months.
You might also be interested in
- Aciclovir, classic antiviral agent for herpes infections
- Valaciclovir, aciclovir prodrug
- Brivudin, another option for herpes zoster
- Foscarnet, for aciclovir resistant herpes strains
- Gabapentin, therapy for postherpetic neuralgia
Frequently asked questions
What is the difference between famciclovir, aciclovir, and valaciclovir?
All three are antiviral nucleoside analogues against herpesviruses. Famciclovir and valaciclovir are prodrugs with significantly better oral bioavailability than aciclovir, allowing less frequent dosing. Clinical efficacy is comparable for most indications. Aciclovir is less expensive and the gold standard for intravenous use, while famciclovir and valaciclovir offer convenience benefits for oral therapy.
When should I take famciclovir for shingles?
As early as possible, ideally within the first 72 hours after typical skin manifestations appear. Later therapy can relieve pain but is less effective at preventing postherpetic neuralgia. If herpes zoster is suspected (band-like rash with pain), medical care should be sought promptly.
Do I need long-term therapy for frequent genital herpes recurrences?
With more than 6 recurrences per year, suppressive therapy with famciclovir 250 mg twice daily may be appropriate. It reduces the frequency of episodes by approximately 70 to 80 percent and transmission risk to sexual partners. Suppressive therapy is usually prescribed for 6 to 12 months and then reevaluated.
Can I combine famciclovir with other medications?
Yes, famciclovir has a favorable drug interaction profile. Caution is warranted with nephrotoxic comedications (NSAIDs, aminoglycosides) and with probenecid, which increases famciclovir levels. Discuss combination therapy briefly with your doctor or pharmacist beforehand.
Sources
- Gelbe Liste, Famciclovir active ingredient profile
- AWMF S2k guideline herpes zoster and postherpetic neuralgia
- BfArM, Federal Institute for Drugs and Medical Devices
- EMA Product information famciclovir preparations
Legal information and disclaimer
The information provided on this page is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendation. It does not replace the advice of a licensed physician or pharmacist. Medications should only be taken as prescribed by a physician or through authorized pharmacy dispensing. All information is based on product information published at the time of creation and recognized scientific sources; the current product information from the manufacturer is always authoritative. Sanoliste assumes no liability for completeness, accuracy, or correctness of the information presented. In a medical emergency, call emergency number 112.